Changes in Biomarkers Using Prostaglandin Inhibitors

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Biomarker Change Linked to Breast Cancer

In brief

This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), act together to decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.

Key facts

Study ID
NCT01769625
Run by
Hartford Hospital
People needed
31
Starts
2009-01-01
Expected to finish
2016-11-01
Last updated by the study team
2017-08-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.